Company Overview of ADC Therapeutics SA
ADC Therapeutics SA develops antibody drug conjugates (ADCs) and non-antibody drug conjugate products. The company is based in Lausanne, Switzerland. ADC Therapeutics SA operates as a subsidiary of Celtic Therapeutics Holdings L.P.
Key Executives for ADC Therapeutics SA
Co-Founder, Chairman and Managing General Partner of Auven Therapeutics
Senior Vice President of Research & Development
Chief Medical Officer and Head of Oncology Clinical Development
Compensation as of Fiscal Year 2015.
ADC Therapeutics SA Key Developments
ADC Therapeutics Sarl Presents at BIO-Europe 2015, Nov-02-2015
Oct 1 15
ADC Therapeutics Sarl Presents at BIO-Europe 2015, Nov-02-2015 . Venue: Munich, Germany.
ADC Therapeutics Announces Board Changes
Sep 28 15
ADC Therapeutics announced that Dr. Hans-Peter Wild and Jacques Theurillat have been appointed to its board of directors as non-executive directors. Dr. Wild is the owner and Chairman of the Wild Group and has built multiple global businesses, including Wild Flavours GmbH. As an independent non executive director, Mr. Theurillat brings to the Board extensive experience in strategy development, finance and commercial operations. He has been CEO of Ares Life Sciences AG and previously served as CEO and Chairman of Albea Pharmaceuticals AG. He also had an extensive career at Serono, which spanned roles such as Chief Financial Officer, Deputy Chief Executive Officer and Senior Executive Vice President, Strategic Corporate Development.
ADC Therapeutics Sarl Announces Executive Changes
Jun 22 15
ADC Therapeutics Sarl announced the appointment of Dr. Chris Martin as its Chief Executive Officer. Dr. Martin was co-founder of Spirogen Ltd. and its Chief Executive Officer. Dr. Martin continued as CEO of Spirogen, and became both a member of Medimmune’s Management Leadership Team and AstraZeneca’s Senior Leaders Group. Dr. Martin will continue to advise Medimmune as a consultant. Dr. Martin replaces Michael Forer who has served as CEO of the company since its formation. Mr. Forer is a Partner in the private equity firm Auven Therapeutics and was the lead investor on behalf of Auven for its majority investments in both Spirogen Ltd. and ADC Therapeutics. The company also announced that Mr. Forer becomes vice chairman of the company, and will continue to work with the company as executive vice president focused on its public markets capital strategy, business and finance activities.
Similar Private Companies By Industry
Recent Private Companies Transactions
September 2, 2015
Most Searched Private Companies
Sponsored Financial Commentaries